Earnings summaries and quarterly performance for UTAH MEDICAL PRODUCTS.
Executive leadership at UTAH MEDICAL PRODUCTS.
Board of directors at UTAH MEDICAL PRODUCTS.
Research analysts covering UTAH MEDICAL PRODUCTS.
Recent press releases and 8-K filings for UTMD.
Utah Medical Products Appoints Director and Increases Quarterly Dividend
UTMD
Board Change
Dividends
- Utah Medical Products, Inc. (UTMD) has appointed Kevin C. Timken, Esq. to its Board of Directors, increasing the board size from five to six members. Mr. Timken will serve on the Audit Committee and Compensation and Benefits Committee.
- The Board of Directors approved a quarterly cash dividend of $0.31 per share of common stock, representing a 1.6% increase over the prior regular quarterly cash dividend.
- This dividend is payable on January 5, 2026, to shareholders of record at the close of business on December 16, 2025.
Nov 4, 2025, 6:42 PM
Utah Medical Products Reports Q2 and First Half 2025 Financial Results
UTMD
Earnings
Share Buyback
Demand Weakening
- For the second calendar quarter (2Q) 2025, consolidated total revenues were $447 (4.3%) lower than in 2Q 2024, and for the first half (1H) 2025, revenues were $2,077 (9.6%) lower than in 1H 2024, primarily due to a continued decline in sales to PendoTECH.
- Gross Profit Margin contracted to 56.2% in 2Q 2025 (from 60.1% in 2Q 2024) and 56.6% in 1H 2025 (from 59.9% in 1H 2024), mainly due to lower sales and an unfavorable product mix for UTMD’s Ireland operations.
- Net Income for 2Q 2025 was $3,048 thousand, a 11.7% decrease from 2Q 2024, and for 1H 2025 was $6,089 thousand, a 17.8% decrease from 1H 2024. Diluted Earnings Per Share (EPS) decreased 4.0% to $0.939 in 2Q 2025 and 10.3% to $1.858 in 1H 2025, with the decline significantly mitigated by share repurchases.
- UTMD maintained a strong balance sheet with no debt, reporting $82.2 million in Cash and Investments as of June 30, 2025. The company repurchased $6.7 million of common stock and paid $2.0 million in dividends during 1H 2025.
Jul 24, 2025, 12:00 AM
Utah Medical Products Reports Q1 2025 Financial Performance
UTMD
Earnings
Share Buyback
- Net sales dropped 14.4% to $9,710 thousand in Q1 2025 versus Q1 2024, driven largely by a significant OEM sales decline, especially from PendoTECH.
- Profitability metrics fell with gross profit down by 18.1%, operating income decreasing 18.8% to $3,154 thousand, and net income falling 23.1% to $3,041 thousand; EPS declined 16% to $0.919.
- The company offset some margin pressure by reducing operating expenses and executed share repurchases, which helped moderate the EPS impact, while maintaining strong liquidity with cash equivalents at $83.3 million and nearly unchanged stockholders’ equity.
Apr 29, 2025, 12:00 AM
Recent SEC filings and earnings call transcripts for UTMD.
No recent filings or transcripts found for UTMD.